Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2015-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.12723PMID 26178713PMCID PMC4631182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.

  2014cited by this paper
• Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

  2013cited by this paper
• In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19.

  2013cited by this paper
• Systematic Review of Population Pharmacokinetic Analyses of Imatinib and Relationships With Treatment Outcomes

  2013cited by this paper
• Without Therapeutic Drug Monitoring, There Is No Personalized Cancer Care

  2013cited by this paper
• Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response

  2013cited by this paper
• Evidence for therapeutic drug monitoring of targeted anticancer therapies.

  2012cited by this paper
• A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

  2012cited by this paper
• Human immunodeficiency virus-associated malignancies: a therapeutic update.

  2012cited by this paper
• Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

  2012cited by this paper
• Potent mechanism‐based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates

  2012cited by this paper
• PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.

  2011cited by this paper
• Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

  2011cited by this paper
• Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy

  2011cited by this paper
• Cancer burden in the HIV-infected population in the United States.

  2011cited by this paper
• Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins

  2011cited by this paper
• Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir

  2010cited by this paper
• Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders

  2009cited by this paper
• Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

  2009cited by this paper
• Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

  2009cited by this paper
• Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development

  2009cited by this paper
• Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.

  2009cited by this paper
• Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC

  2008cited by this paper
• Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. III. In Vitro-in Vivo Correlation with Fluconazole

  2008cited by this paper
• Imatinib for hepatocellular cancer--focus on pharmacokinetic/pharmacodynamic modelling and liver function.

  2008cited by this paper
• Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients

  2008cited by this paper
• Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

  2008cited by this paper
• Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. II. In Vitro-in Vivo Correlation with Ketoconazole

  2008cited by this paper
• Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.

  2007cited by this paper
• Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

  2007cited by this paper
• Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib

  2007cited by this paper
• Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa

  2007cited by this paper
• Comparison of Intrinsic Clearance in Liver Microsomes and Hepatocytes from Rats and Humans: Evaluation of Free Fraction and Uptake in Hepatocytes

  2006cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

  2006cited by this paper
• Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

  2006cited by this paper
• METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS

  2005cited by this paper
• Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8

  2005cited by this paper
• A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES

  2005cited by this paper
• Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.

  2005cited by this paper
• Therapeutic Drug Monitoring and Drug–Drug Interactions Involving Antiretroviral Drugs

  2005cited by this paper
• Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

  2005cited by this paper
• Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: Comparison among well-stirred, parallel-tube, distributed and dispersion models

  2005cited by this paper
• Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

  2004cited by this paper
• The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate

  2004cited by this paper
• Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.

  2004cited by this paper
• Effect of St John's Wort on imatinib mesylate pharmacokinetics

  2004cited by this paper
• Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion

  2004cited by this paper
• Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects

  2004cited by this paper
• Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.

  2004cited by this paper
• Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

  2004cited by this paper
• Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.

  2003cited by this paper
• Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

  2003cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Interactions among drugs for HIV and opportunistic infections.

  2001cited by this paper
• Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors

  2001cited by this paper
• Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.

  1999cited by this paper
• Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction.

  1999cited by this paper
• Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities.

  1998cited by this paper
• Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes.

  1998cited by this paper
• Inhibition and Induction of Cytochrome P450 and the Clinical Implications

  1998cited by this paper

• Pharmacotherapeutic monitoring of tyrosine kinase inhibitors use in patients with chronic myeloid leukaemia: An integrative model proposal.

  2026cites this paper
• Interindividual variability in imatinib metabolism in human liver microsomes and primary human hepatocytes: Impact of CYP2C8 and CYP3A phenotypes.

  2025cites this paper
• A Review on New Frontiers in Drug-Drug Interaction Predictions and Safety Evaluations with In Vitro Cellular Models

  2025cites this paper
• A cocktail probe approach to evaluate the effect of hormones on the expression and activity of CYP enzymes in human hepatocytes with conditions simulating late stage of pregnancy

  2023cites this paper
• Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia

  2020cites this paper
• Paclitaxel, Imatinib and 5-Fluorouracil Increase the Unbound Fraction of Flucloxacillin In Vitro

  2020cites this paper
• Modelling drugs interaction in treatment-experienced patients on antiretroviral therapy

  2020cites this paper
• Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo

  2019cites this paper
• Toxische Effekte vermeiden

  2018cites this paper
• Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities

  2017cites this paper